The FDA has dubbed Regeneron Pharmaceuticals' and Sanofi's experimental atopic dermatitis drug dupilumab a breakthrough therapy – a status intended to expedite the regulatory process.
As of 14 November – the most recent date for which data are available – the FDA's Center for Drug...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
